Single-Dose PK/Safety of DTG-Dispersible Tablets in Neonates Supports Multi-Dosing: Petite-DTG Study
Background: Dolutegravir dispersible tablets (DTG-DT) are approved for infants ≥3 kg and aged >4 weeks but their suitability for neonates remains unknown. We evaluated the pharmacokinetics (PK) and safety of pediatric DTG-DT in neonates born to women on DTG-based therapy. Methods: PETITE-DTG is an ongoing phase I/II, open-label, single center, two-stage trial in South Africa…